Advanced Biotherapy, Inc.

U.S. patent granted for asthma, allergy treatment

Published in Drug Law Weekly, June 29th, 2004

Advanced Biotherapy, Inc., (ADVB) announced that it has received a Notice of Allowance from the United States Patent and Trademark Office for its patent application entitled "Methods of prevention and treatment of asthma and allergic conditions."

Commenting on this announcement, Edmond Buccellato, CEO, stated: "Our patented treatment is directed at two of the main mediators of allergy and bronchial asthma, IgE and histamine. IgE is an immunoglobulin that plays a role in stimulating release of histamine. This release of histamine induces the allergic reaction that is the hallmark of the disease. It is one of the substances responsible for the symptoms of inflammation and...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Drug Law Weekly

Source: Drug Law Weekly (2004-06-29)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry